

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and
Waiver under 18 U.S.C. § 208(b)(3)

Steven E. Gay, M.D., M.S.

Committees: Joint Nonprescription Drugs Advisory Committee and Pulmonary Allergy Drug
Advisory Committee Meeting

Meeting Date: January 24, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to discussions of the continued need for the designation of over-the-counter (OTC) epinephrine-metered dose inhalers (MDIs) for the treatment of asthma as an essential use of ozone-depleting substances under 21 CFR 2.125, I am eligible to receive a waiver under 18 U.S.C. § 208(b)(3).

Type of Interest	Nature	Magnitude
Speaker's Bureau	Affected Company	Less than \$10,001 per year
Speaker's Bureau	Affected Company	Less than \$10,001 per year
Speaker's Bureau	Affected Company	From \$10,001 to \$50,000 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

Signature of SGE

12/22/05

Date